Latest Immunomic Therapeutics Inc. Stories
Fast Growing Biotech Company Strengthens Resources Hershey, PA & Rockville, MD (PRWEB) February 10, 2015 Immunomic Therapeutics, Inc.
HERSHEY, Pa., Rockville, Md. and TOKYO, Jan. 29, 2015 /PRNewswire/ -- Immunomic Therapeutics, Inc.
Immunomic Therapeutics will be presenting the current state of the Company and its significant progress over the past year on executing on its plan and building investor value Hershey,
Immunomic Therapeutics, Inc., (ITI), and Bioject have entered into an agreement for ITI to use Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ vaccine platform.
Discussions with the Japanese Pharmaceutical Medical Device Agency (PMDA) achieved a clear regulatory pathway and acceptance of Immunomic Therapeutics’ LAMP-vax DNA vaccine technologies to continue
Proceeds from the financing will be used to advance the development of products for the treatment of Japanese red cedar and peanut allergy HERSHEY, PA &
ITI has submitted a new IND for a Phase II clinical study of the JRC Vaccine Hershey, PA & Rockville, MD (PRWEB) October 01, 2014 DNA Vaccine pioneer
The $255,000 award will help ITI conduct vaccine validation studies over one year Hershey, PA & Rockville, MD (PRWEB) September 17, 2014 Immunomic
ITI moves one step closer to a solution for the worldwide allergy crisis. Hershey, PA & Rockville, MD (PRWEB) August 21, 2014 DNA vaccine pioneer